select a format

Single User License
USD 2000 INR 128140
Site License
USD 4000 INR 256280
Corporate User License
USD 6000 INR 384420

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Huntington Disease-Pipeline Review, H2 2016

Huntington Disease-Pipeline Review, H2 2016


  • Products Id :- GMDHC8805IDB
  • |
  • Pages: 292
  • |
  • December 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Huntington Disease-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Huntington Disease-Pipeline Review, H2 2016, provides an overview of the Huntington Disease (Central Nervous System) pipeline landscape.

Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Huntington Disease-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Huntington Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10, 5, 46 and 17 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 19 and 4 molecules, respectively.Huntington Disease.

Huntington Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Huntington Disease (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Huntington Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Huntington Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Huntington Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Huntington Disease (Central Nervous System)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Huntington Disease (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Huntington Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

Introduction 5

Huntington Disease Overview 6

Therapeutics Development 7

Huntington Disease-Therapeutics under Development by Companies 9

Huntington Disease-Therapeutics under Investigation by Universities/Institutes 13

Huntington Disease-Pipeline Products Glance 15

Huntington Disease-Products under Development by Companies 18

Huntington Disease-Products under Investigation by Universities/Institutes 23

Huntington Disease-Companies Involved in Therapeutics Development 24

Huntington Disease-Therapeutics Assessment 80

Drug Profiles 91

Huntington Disease-Dormant Projects 260

Huntington Disease-Discontinued Products 268

Huntington Disease-Product Development Milestones 269

Appendix 279

List of Figures

Number of Products under Development for Huntington Disease, H2 2016 19

Number of Products under Development for Huntington Disease-Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Investigation by Universities/Institutes, H2 2016 25

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Products, H2 2016 29

Assessment by Monotherapy Products, H2 2016 92

Number of Products by Top 10 Targets, H2 2016 93

Number of Products by Stage and Top 10 Targets, H2 2016 93

Number of Products by Top 10 Mechanism of Actions, H2 2016 96

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 96

Number of Products by Top 10 Routes of Administration, H2 2016 99

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 99

Number of Products by Top 10 Molecule Types, H2 2016 101

Number of Products by Stage and Top 10 Molecule Types, H2 2016 101

List of Tables

Number of Products under Development for Huntington Disease, H2 2016 19

Number of Products under Development for Huntington Disease-Comparative Analysis, H2 2016 20

Number of Products under Development by Companies, H2 2016 21

Number of Products under Development by Companies, H2 2016 (Contd..1) 22

Number of Products under Development by Companies, H2 2016 (Contd..2) 23

Number of Products under Development by Companies, H2 2016 (Contd..3) 24

Number of Products under Investigation by Universities/Institutes, H2 2016 26

Comparative Analysis by Late Stage Development, H2 2016 27

Comparative Analysis by Clinical Stage Development, H2 2016 28

Comparative Analysis by Early Stage Development, H2 2016 29

Products under Development by Companies, H2 2016 30

Products under Development by Companies, H2 2016 (Contd..1) 31

Products under Development by Companies, H2 2016 (Contd..2) 32

Products under Development by Companies, H2 2016 (Contd..3) 33

Products under Development by Companies, H2 2016 (Contd..4) 34

Products under Investigation by Universities/Institutes, H2 2016 35

Huntington Disease-Pipeline by Addex Therapeutics Ltd, H2 2016 36

Huntington Disease-Pipeline by AFFiRiS AG, H2 2016 37

Huntington Disease-Pipeline by Angita BV, H2 2016 38

Huntington Disease-Pipeline by Annexon Inc, H2 2016 39

Huntington Disease-Pipeline by Astellas Pharma Inc, H2 2016 40

Huntington Disease-Pipeline by Azevan Pharmaceuticals Inc, H2 2016 41

Huntington Disease-Pipeline by BioCrea GmbH, H2 2016 42

Huntington Disease-Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016 43

Huntington Disease-Pipeline by Celon Pharma Sp z oo, H2 2016 44

Huntington Disease-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 45

Huntington Disease-Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 46

Huntington Disease-Pipeline by EncephRx Inc, H2 2016 47

Huntington Disease-Pipeline by Evotec AG, H2 2016 48

Huntington Disease-Pipeline by Galenea Corp, H2 2016 49

Huntington Disease-Pipeline by Genervon Biopharmaceuticals LLC, H2 2016 50

Huntington Disease-Pipeline by Horizon Pharma Plc, H2 2016 51

Huntington Disease-Pipeline by Immungenetics AG, H2 2016 52

Huntington Disease-Pipeline by Ionis Pharmaceuticals Inc, H2 2016 53

Huntington Disease-Pipeline by Ipsen SA, H2 2016 54

Huntington Disease-Pipeline by Kadmon Corp LLC, H2 2016 55

Huntington Disease-Pipeline by KineMed Inc, H2 2016 56

Huntington Disease-Pipeline by Krenitsky Pharmaceuticals Inc, H2 2016 57

Huntington Disease-Pipeline by Living Cell Technologies Ltd, H2 2016 58

Huntington Disease-Pipeline by Medesis Pharma SA, H2 2016 59

Huntington Disease-Pipeline by Mitochon Pharmaceuticals Inc, H2 2016 60

Huntington Disease-Pipeline by Neuralstem Inc, H2 2016 61

Huntington Disease-Pipeline by Neurimmune Holding AG, H2 2016 62

Huntington Disease-Pipeline by NeuroNascent Inc, H2 2016 63

Huntington Disease-Pipeline by New World Laboratories Inc, H2 2016 64

Huntington Disease-Pipeline by nLife Therapeutics SL, H2 2016 65

Huntington Disease-Pipeline by NsGene A/S, H2 2016 66

Huntington Disease-Pipeline by Omeros Corp, H2 2016 67

Huntington Disease-Pipeline by Oryzon Genomics SA, H2 2016 68

Huntington Disease-Pipeline by Pfizer Inc, H2 2016 69

Huntington Disease-Pipeline by PharmatrophiX Inc, H2 2016 70

Huntington Disease-Pipeline by ProQR Therapeutics NV, H2 2016 71

Huntington Disease-Pipeline by QR Pharma Inc, H2 2016 72

Huntington Disease-Pipeline by reMYND NV, H2 2016 73

Huntington Disease-Pipeline by Retrotope Inc, H2 2016 74

Huntington Disease-Pipeline by Rhenovia Pharma Ltd, H2 2016 75

Huntington Disease-Pipeline by Shire Plc, H2 2016 76

Huntington Disease-Pipeline by SOM Biotech SL, H2 2016 77

Huntington Disease-Pipeline by Spark Therapeutics Inc, H2 2016 78

Huntington Disease-Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 79

Huntington Disease-Pipeline by TyrNovo Ltd, H2 2016 80

Huntington Disease-Pipeline by Ultragenyx Pharmaceutical Inc, H2 2016 81

Huntington Disease-Pipeline by UniQure NV, H2 2016 82

Huntington Disease-Pipeline by Vaccinex Inc, H2 2016 83

Huntington Disease-Pipeline by Vertex Pharmaceuticals Inc, H2 2016 84

Huntington Disease-Pipeline by VistaGen Therapeutics Inc, H2 2016 85

Huntington Disease-Pipeline by Vitality Biopharma Inc, H2 2016 86

Huntington Disease-Pipeline by VivaCell Biotechnology Espana SL, H2 2016 87

Huntington Disease-Pipeline by Voyager Therapeutics Inc, H2 2016 88

Huntington Disease-Pipeline by Vybion Inc, H2 2016 89

Huntington Disease-Pipeline by WAVE Life Sciences Ltd, H2 2016 90

Huntington Disease-Pipeline by Wellstat Therapeutics Corp, H2 2016 91

Assessment by Monotherapy Products, H2 2016 92

Number of Products by Stage and Target, H2 2016 94

Number of Products by Stage and Mechanism of Action, H2 2016 97

Number of Products by Stage and Route of Administration, H2 2016 100

Number of Products by Stage and Molecule Type, H2 2016 102

Huntington Disease-Dormant Projects, H2 2016 272

Huntington Disease-Dormant Projects (Contd..1), H2 2016 273

Huntington Disease-Dormant Projects (Contd..2), H2 2016 274

Huntington Disease-Dormant Projects (Contd..3), H2 2016 275

Huntington Disease-Dormant Projects (Contd..4), H2 2016 276

Huntington Disease-Dormant Projects (Contd..5), H2 2016 277

Huntington Disease-Dormant Projects (Contd..6), H2 2016 278

Huntington Disease-Dormant Projects (Contd..7), H2 2016 279

Huntington Disease-Discontinued Products, H2 2016 280

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd , AFFiRiS AG , Angita BV , Annexon Inc , Astellas Pharma Inc , Azevan Pharmaceuticals Inc , BioCrea GmbH , BrainStorm Cell Therapeutics Inc , Celon Pharma Sp z oo , Chong Kun Dang Pharmaceutical Corp , Diffusion Pharmaceuticals Inc , EncephRx Inc , Evotec AG , Galenea Corp , Genervon Biopharmaceuticals LLC , Horizon Pharma Plc , Immungenetics AG , Ionis Pharmaceuticals Inc , Ipsen SA , Kadmon Corp LLC , KineMed Inc , Krenitsky Pharmaceuticals Inc , Living Cell Technologies Ltd , Medesis Pharma SA , Mitochon Pharmaceuticals Inc , Neuralstem Inc , Neurimmune Holding AG , NeuroNascent Inc , New World Laboratories Inc , nLife Therapeutics SL , NsGene A/S , Omeros Corp , Oryzon Genomics SA , Pfizer Inc , PharmatrophiX Inc , ProQR Therapeutics NV , QR Pharma Inc , reMYND NV , Retrotope Inc , Rhenovia Pharma Ltd , Shire Plc , SOM Biotech SL , Spark Therapeutics Inc , Teva Pharmaceutical Industries Ltd , TyrNovo Ltd , Ultragenyx Pharmaceutical Inc , UniQure NV , Vaccinex Inc , Vertex Pharmaceuticals Inc , VistaGen Therapeutics Inc , Vitality Biopharma Inc , VivaCell Biotechnology Espana SL , Voyager Therapeutics Inc , Vybion Inc , WAVE Life Sciences Ltd , Wellstat Therapeutics Corp

Huntington Disease Therapeutic Products under Development, Key Players in Huntington Disease Therapeutics, Huntington Disease Pipeline Overview, Huntington Disease Pipeline, Huntington Disease Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com